Rhythm Pharmaceuticals, Inc.: Diferență între versiuni

Pagina dedicata companiei Rhythm Pharmaceuticals, Inc. listata cu simbolul US.RYTM

Rhythm Pharmaceuticals, Inc. (http://www.rhythmtx.com) is a commercial-stage biopharmaceutical company. The Company is focused on developing treatment for genetic diseases of obesity, which are characterized by early-onset, severe obesity and an insatiable hunger (hyperphagia). Its lead product candidate, IMCIVREE (setmelanotide), is a potent melanocortin-4 receptor (MC4R). IMCIVREE is developed for the treatment of rare genetic diseases of obesity. It is focused on the melanocortin-4 receptor (MC4R) pathway, which is responsible for regulating weight and hunger. It targets the MC4R pathway to develop therapeutics for rare genetic diseases of obesity, including proopiomelanocortin (POMC) deficiency obesity, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl syndrome (BBS), Alstrom syndrome, POMC or LEPR heterozygous deficiency obesity, Smith-Magenis syndrome, steroid receptor coactivator 1 (SRC1) deficiency obesity, MC4R deficiency obesity and SH2B adapter protein 1 (SH2B1) deficiency obesity.

==Ultimele stiri despre Rhythm Pharmaceuticals, Inc. (US.RYTM)==

addfirstcategorydate=false

</dynamicpagelist>

[[Categorie:US.RYTM]][[Categorie:Stiri despre companii]]